---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-104574"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:42:12.268236+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Intellia Q2 net loss narrows to $101.3M; Phase 3 enrollment ahead; CMO to retire in 2026

## Summary
- Net loss $101.3M in Q2 2025 vs $147.0M a year ago; collaboration revenue $14.2M (up from $6.9M).
- Cash, equivalents and marketable securities $630.5M as of June 30, expected to fund ops into H1 2027.
- Phase 3 MAGNITUDE (ATTR-CM) enrollment ahead; study expanded from 765 to ~1,200 patients.
- Phase 3 HAELO (HAE) randomization expected to complete in Q3 2025; BLA submission targeted H2 2026.
- CMO Dr. David Lebwohl to retire effective Aug 7, 2026; will continue in role until successor appointed.

## SEC filing metadata
- accession: 0000950170-25-104574
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000095017025104574/0000950170-25-104574-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000095017025104574/ntla-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-104574
- JSON: https://secwatch.observer/filing/0000950170-25-104574.json
- Plain text: https://secwatch.observer/filing/0000950170-25-104574.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.